Mount Sinai’s multifaceted research portfolio reflects its unwavering commitment to confronting some of oncology’s most challenging frontiers. This year’s presentations span a diverse spectrum of cancer specialties, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, translational science, and cancer care delivery. The breadth and depth of these contributions underscore Mount Sinai’s role as a leader in developing sophisticated, personalized approaches to cancer therapy—approaches that marry benchside discoveries with bedside applications.

Among the highlights is a highly anticipated late-breaking oral presentation by Dr. John Mascarenhas, Professor of Medicine and Director of the Center of Excellence for Blood Cancer and Myeloid Disorders at Mount Sinai Tisch Cancer Center. Dr. Mascarenhas will reveal pivotal results from the phase 3 SENTRY trial, which evaluates the combination of selinexor and ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis. This trial explores a novel therapeutic strategy designed to inhibit aberrant signaling pathways responsible for the proliferation of malignant hematopoietic cells. Scheduled for June 2 during the Hematologic Malignancies oral abstract session, these findings hold significant promise for patients with this debilitating myeloproliferative disorder.

In the arena of thoracic oncology, Mount Sinai investigators are advancing the frontier of immunotherapy through research on HLX43, an anti-PD-L1 antibody-drug conjugate. This Rapid Oral Abstract Session presentation examines HLX43’s efficacy and safety in patients with advanced non-small cell lung cancer (NSCLC), delving into its potential to harness immune checkpoint inhibition to augment tumor targeting and destruction. Antibody-drug conjugates represent a cutting-edge modality designed to deliver cytotoxic agents directly to cancer cells while minimizing off-target effects.

Beyond these oral sessions, Mount Sinai’s robust research pipeline includes a variety of poster presentations tackling pressing questions across multiple cancer types. Studies investigating macrophage polarization in metastatic urothelial cancer highlight the CXCL9:SPP1 ratio as a predictive biomarker for response to pembrolizumab and enfortumab vedotin combination therapies. This work provides new insights into tumor microenvironment dynamics, emphasizing the role of immune cell modulation in therapeutic outcomes.

Additional poster research assesses national trends in immunotherapy use among patients with metastatic head and neck squamous cell carcinoma, employing data from the National Cancer Database. These epidemiological studies reveal critical patterns in end-of-life treatment, ultimately guiding more compassionate and effective care strategies. Further work from Mount Sinai evaluates overall survival patterns in mucosal melanoma patients before and after the widespread adoption of PD-1 based checkpoint inhibitors, shedding light on the transformative impact of immunotherapy in rare and aggressive malignancies.

Investigations into relapsed/refractory multiple myeloma feature comparative analyses of belantamab mafodotin added to bortezomib and dexamethasone versus standard of care. These studies are instrumental in refining therapeutic algorithms and optimizing patient outcomes in a disease known for its complexity and heterogeneity. On the biomarker frontier, research on Keratin 19 (KRT19) as a circulating tumor biomarker offers a promising avenue for non-invasive disease monitoring and treatment guidance in urothelial carcinoma.

Cutting-edge molecular diagnostics are also exemplified by studies evaluating pre-cystectomy circulating tumor DNA (ctDNA) levels to differentiate patients with surgically curable disease from those harboring occult micrometastatic progression. These advances could pave the way for precision staging and personalized adjuvant therapy strategies, revolutionizing bladder cancer management.

Mount Sinai clinicians continue to pioneer novel immunomodulatory therapeutic concepts, such as trials investigating tolododekin alfa (ANK-101) in combination with anti-PD-1/PD-L1 antibodies in advanced NSCLC. This phase 1b study aims to potentiate immune responses by modulating cytokine environments, potentially overcoming resistance mechanisms inherent to checkpoint blockade monotherapy.

Urothelial carcinoma research remains a central focus, exemplified by multiple studies including the CheckMate-901 trial examining biomarker profiles associated with durable disease control in advanced disease treated with nivolumab plus ipilimumab. Similarly, the TROPION-Urothelial03 trial compares datopotamab deruxtecan plus chemotherapy versus the current standard of care in heavily pretreated patients, illustrating Mount Sinai’s commitment to improving outcomes in this challenging cancer subtype.

In the realm of myelofibrosis, the MY-PAC study investigates treatment patterns and clinical outcomes among patients treated with pacritinib, especially those with higher platelet counts. This research helps elucidate safety and efficacy profiles critical to managing this patient population. Additionally, updates on IMPROVEMF, a phase 1b trial combining imetelstat and ruxolitinib in intermediate and high-risk myelofibrosis, signify ongoing efforts to enhance therapeutic benefits and address unmet clinical needs.

The Mount Sinai Tisch Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, remains at the forefront of integrating basic, clinical, and population health research. With a strategic focus on tumor types prevalent in its catchment area—including liver, prostate, breast, bladder, and lung cancers—Mount Sinai is uniquely positioned to translate cutting-edge research into meaningful advancements in patient care. Its extensive network, encompassing seven hospitals and over 400 physician practices, allows Mount Sinai to deliver multidisciplinary expertise alongside a growing portfolio of innovative clinical trials.

Notably, the construction of the soon-to-be-completed Mount Sinai Tisch Cancer Hospital will further augment the center’s capacity for pioneering research and patient-centered care, equipped with state-of-the-art facilities designed to accelerate translational research and clinical innovation. As these advancements unfold, Mount Sinai continues to steer oncology toward a future where personalized medicine transforms prognosis and quality of life for patients worldwide.

For more information about the ASCO Annual Meeting and to explore the full breadth of research presented by Mount Sinai, visit the official ASCO Annual Meeting website.

Subject of Research: Cancer research, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, immunotherapy, biomarker-driven approaches, multiple myeloma, and myelofibrosis.

Article Title: Mount Sinai Tisch Cancer Center Unveils Breakthrough Cancer Research at ASCO 2026 Annual Meeting

News Publication Date: May 27, 2026

Web References:

• https://www.asco.org/annual-meeting
• https://www.asco.org/abstracts-presentations/262643
• https://www.asco.org/abstracts-presentations/263356
• https://www.asco.org/abstracts-presentations/261730
• https://www.asco.org/abstracts-presentations/267968
• https://www.asco.org/abstracts-presentations/260701
• https://www.asco.org/abstracts-presentations/262647
• https://www.asco.org/abstracts-presentations/266782
• https://www.asco.org/abstracts-presentations/262606
• https://www.asco.org/abstracts-presentations/266904
• https://www.asco.org/abstracts-presentations/267846
• https://www.asco.org/abstracts-presentations/266659

Keywords: Myelofibrosis, hematologic malignancies, antibody-drug conjugates, immunotherapy, non-small cell lung cancer, urothelial carcinoma, circulating tumor DNA, biomarker-driven treatment, multiple myeloma, PD-1 checkpoint inhibitors, cancer clinical trials, personalized cancer therapy.

Hypofractionated radiotherapy (HypoRT) deviates from traditional fractionation by delivering higher doses of radiation per session over fewer treatments, thereby shortening the overall course of radiation therapy. This approach has gained traction in recent years, particularly in thoracic oncology, as it promises a more patient-centric treatment schedule while potentially minimizing cumulative toxicities associated with prolonged radiotherapy. Recognizing the dire need for improved treatment modalities in LS-SCLC, the trial sought to meticulously assess whether HypoRT could maintain efficacy without compromising safety.

The extensive study encompassed 530 patients across 16 tertiary hospitals in China, meticulously randomized to receive either the hypofractionated radiation dosing of 45 Gray (Gy) administered in 15 daily fractions over three weeks or the conventional fractionated dosing of 60 Gy in 30 daily fractions spanning six weeks. Both arms were coordinated with standard platinum-based chemotherapy regimens including cisplatin or carboplatin combined with etoposide, ensuring uniform systemic treatment across participants.

After a median follow-up period extending beyond 43 months, survival analysis revealed that median overall survival was 40.2 months for the HypoRT group as opposed to 47.9 months for the conventional radiotherapy (ConvRT) cohort. The calculated hazard ratio (HR) of 1.04, with a 95% confidence interval ranging from 0.81 to 1.33, indicated no statistically significant difference in survival outcomes between the two treatment paradigms. Progression-free survival (PFS), another crucial endpoint reflecting the time patients remained free from disease progression, similarly showed no meaningful divergence.

Importantly, the condensed HypoRT regimen conferred tangible advantages in terms of treatment tolerability. Patients subjected to hypofractionated schedules encountered significantly lower incidences of severe treatment-related adverse events, particularly hematologic toxicity, lymphopenia, and radiation pneumonitis. The prevalence of acute grade 3 or higher toxicities was notably reduced from 67.7% in the ConvRT group to 48.7% within the HypoRT cohort. These declines in adverse event rates suggest that HypoRT not only streamlines therapy duration but also potentially improves the overall quality of life for patients undergoing intensive cancer treatment.

Dr. Nan Bi from The National Cancer Center of China emphasized the clinical relevance of these findings, stating, “Our data validate that hypofractionated radiotherapy can provide a shorter, more convenient treatment course with fewer side effects while maintaining comparable survival outcomes to conventional radiotherapy.” This could be particularly transformative in healthcare environments where resource optimization and patient throughput are critical considerations.

The biological rationale underlying hypofractionation’s comparable efficacy may relate to radiobiological principles involving tumor cell kill dynamics and normal tissue repair mechanisms. The delivery of higher doses per fraction is theorized to achieve greater tumor cytotoxicity, potentially offsetting the shorter overall treatment time. Concurrent chemotherapy synergistically promotes tumor suppression by addressing systemic microscopic disease, a crucial factor given the propensity of small cell lung cancer for early dissemination.

Moreover, the researchers highlighted the potential immunomodulatory effects of hypofractionated radiation. Unlike conventional fractionation, HypoRT may more effectively spare immune cell populations, particularly lymphocytes, from radiation-induced depletion, thereby preserving or even enhancing antitumor immune responses. This finding underscores promising avenues for combining HypoRT with emerging immunotherapeutic agents, a strategy the investigators advocate for in future clinical trials.

Small cell lung cancer accounts for approximately 10-15% of all lung cancer diagnoses and is characterized by rapid growth, early metastasis, and a generally poor prognosis. Limited-stage disease, wherein the malignancy is confined to one hemithorax and regional lymph nodes, remains the window where curative intent treatment is feasible. Historically, standard care has entailed a six-week course of conventional fractionated radiotherapy with concurrent chemotherapy, although the prolonged treatment duration imposes logistical and patient quality-of-life challenges.

The phase III trial’s results contribute critical evidence supporting the adoption of hypofractionated schedules as a new standard of care, offering an effective, more tolerable alternative that may enhance patient adherence. Adoption of HypoRT could reduce the burden on radiotherapy infrastructure while improving patient convenience, factors of increasing importance in the era of personalized oncology care.

These findings, disclosed at the IASLC WCLC 2025—the foremost global meeting addressing lung cancer advancements—represent a significant milestone. The IASLC, a professional network uniting over 10,000 experts worldwide, continues to spearhead efforts to accelerate lung cancer research dissemination and clinical implementation. The WCLC conference attracts the largest assembly of thoracic oncology specialists and serves as a premier platform for unveiling innovative clinical trial data, as evidenced by this landmark study.

With the growing paradigm shift towards integrating multimodal therapies, the emerging data on HypoRT’s immune-sparing effects encourage further investigation into combined regimens pairing hypofractionated radiation with immune checkpoint inhibitors or other immunotherapies. Such combinations hold the promise of amplifying therapeutic efficacy while keeping toxicity manageable, potentially redefining treatment algorithms for LS-SCLC.

As the oncology community digests these results, there is cautious optimism that the validation of HypoRT could markedly enhance clinical practice worldwide. The streamlined protocol not only aligns with patient-centered care principles but also offers a strategic approach to reduce radiotherapy wait times, optimize resource allocation, and expand treatment accessibility globally.

In conclusion, this rigorous phase III study clearly establishes that hypofractionated radiotherapy with concurrent chemotherapy achieves survival parity with conventional six-week regimens in limited-stage small cell lung cancer, accompanied by a favorable toxicity profile. The evidence advocates for broader multidisciplinary consideration of HypoRT as a standard treatment option and paves the way for innovative trials integrating immunotherapy to fully exploit its promising therapeutic potential.

Subject of Research: Radiotherapy regimens in limited-stage small cell lung cancer (LS-SCLC)
Article Title: Shorter Hypofractionated Radiotherapy with Chemotherapy Matches Conventional Treatment in LS-SCLC with Reduced Toxicity
News Publication Date: September 8, 2025
Web References: www.iaslc.org
Keywords: Lung cancer, small cell lung cancer, hypofractionated radiotherapy, limited-stage disease, chemotherapy, radiation toxicity, phase III trial, concurrent chemoradiotherapy, radiation pneumonitis, immunotherapy integration

NSCLC, particularly when centrally located, presents formidable challenges due to its aggressive nature and anatomical proximity to vital bronchovascular structures. The conventional mainstay treatment—pneumonectomy—involves removal of an entire lung but carries significant risks. High rates of morbidity and mortality, along with drastic reductions in pulmonary reserve, frequently compromise patients’ quality of life and limit opportunities for additional adjuvant therapies. As such, the thoracic surgery community has increasingly sought lung-parenchyma-preserving interventions, with bronchoplasty techniques and sleeve lobectomy emerging as promising alternatives that balance oncologic control with functional preservation.

Sleeve lobectomy (SL), which entails resection of the lung lobe along with a segment of the bronchus and subsequent bronchial reconstruction, has demonstrated superior survival and postoperative pulmonary function compared to pneumonectomy. However, when the extent of tumor involvement precludes a standard sleeve lobectomy (SSL), surgical options become severely constrained. Extended sleeve lobectomy (ESL)—a more complex procedure involving resection and reconstruction of additional airway and vascular structures—has been proposed to circumvent the need for pneumonectomy, yet its safety profile, particularly after neoadjuvant immunochemotherapy, has remained uncertain.

Neoadjuvant immunochemotherapy, combining immune checkpoint inhibitors with chemotherapy agents prior to surgery, has transformed the treatment landscape for NSCLC by enhancing tumor downstaging and potentially improving long-term survival. While the safety and feasibility of SSL in the context of this novel systemic approach have been documented, ESL’s role post-immunochemotherapy has remained largely unexplored until now. This study addresses that knowledge gap by meticulously analyzing outcomes of ESL in patients treated with neoadjuvant immunochemotherapy, comparing morbidity, oncological radicality, and survival against those undergoing SSL or PN.

The investigators retrospectively reviewed 94 cases of centrally located NSCLC patients who received neoadjuvant immunochemotherapy, followed by either pneumonectomy, ESL, or SSL. Remarkably, complete R0 resections—indicating no microscopic residual tumor—were achieved in 95.7% of these cases. The R0 resection rates were comparably high across groups: 94.4% in ESL, 97.6% in SSL, and 94.1% in PN, underscoring the oncological rigor of ESL despite its technical complexity. This finding challenges skepticism that ESL may compromise surgical radicality when compared to more conventional approaches.

In terms of postoperative complications, the overall rate was relatively contained at 18.1%. While patients who underwent pneumonectomy experienced a higher complication rate of 32.4%, no statistically significant difference was detected between ESL and PN groups. Importantly, the ESL group’s morbidity rates closely paralleled those seen with the technically less demanding SSL, supporting ESL’s safety in adept hands following neoadjuvant immunochemotherapy. These results defy entrenched assumptions that extended resection and reconstruction inherently lead to prohibitive perioperative risks.

Long-term outcomes further bolster ESL’s standing as a viable alternative. Kaplan–Meier survival analyses revealed no significant difference in event-free survival between ESL and SSL, indicating that the extended surgical approach does not compromise prognosis. Strikingly, patients undergoing ESL demonstrated a statistically significant advantage in event-free survival compared to those receiving pneumonectomy (P=0.04). Such data suggest that ESL not only preserves lung tissue and function but may also confer improved oncological outcomes in this high-risk population.

The clinical ramifications of these findings are profound. ESL after neoadjuvant immunochemotherapy presents a technically complex but feasible and oncologically sound option that mitigates the devastating functional losses associated with pneumonectomy. By preserving greater lung parenchyma, ESL can maintain higher pulmonary reserves, reduce perioperative morbidity, and facilitate access to subsequent adjuvant therapies—elements crucial for enhancing patient quality of life and survival. This approach epitomizes precision surgery in thoracic oncology, aligning therapeutic aggressiveness with the imperative to safeguard physiological function.

Furthermore, the study underscores the importance of multidisciplinary collaboration, integrating cutting-edge systemic therapies with advanced surgical techniques. The interplay between neoadjuvant immunochemotherapy’s tumor-shrinking effects and ESL’s parenchymal-sparing strategy exemplifies a paradigm shift. It signals a move away from one-size-fits-all pneumonectomy toward individualized, multimodal treatments tailored to tumor extent, patient fitness, and functional status.

Despite these encouraging results, ESL remains a technically demanding procedure necessitating high surgical expertise and careful patient selection. Thorough preoperative assessment—including detailed imaging and bronchoscopic evaluation—is paramount to delineate tumor boundaries and plan airway reconstructions. Likewise, perioperative management must anticipate potential complications inherent to extensive bronchovascular reconstructions, necessitating experienced surgical teams and comprehensive postoperative care.

Critically, this study’s findings advocate for broadening the surgical repertoire available to thoracic surgeons treating central NSCLC. Adoption of ESL post-neoadjuvant immunochemotherapy promises to reduce reliance on pneumonectomy, potentially translating into better postoperative function and survival outcomes for a patient subset historically tethered to more radical resections. The implications extend beyond individual patient benefit, potentially reshaping clinical guidelines and influencing training paradigms within thoracic surgery.

This evidence further highlights the transformative role neoadjuvant immunochemotherapy plays in optimizing surgical candidacy and outcomes. By effectively downstaging tumors, this systemic approach increases the feasibility of lung-sparing techniques like ESL. It reflects a new frontier in NSCLC management, where the integration of immunotherapy and advanced surgical modalities converge to improve both oncologic control and patient-centered outcomes.

In summary, the study by He, Li, and colleagues marks a milestone in thoracic oncology, establishing extended sleeve lobectomy following neoadjuvant immunochemotherapy as a safe, effective, and function-preserving surgical option for centrally located NSCLC. These findings invite thoracic surgeons worldwide to consider ESL as a potent alternative to pneumonectomy, particularly when standard sleeve lobectomy is insufficient for achieving complete tumor removal. As research in immunotherapy and surgical techniques evolves, such multidisciplinary approaches will be pivotal in redefining standards of care for lung cancer, ultimately translating into better survival and quality of life for patients.

Subject of Research: People

Article Title: Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer

News Publication Date: 9-Apr-2025

Web References: http://dx.doi.org/10.1016/j.athoracsur.2025.03.033

Keywords: Lung cancer, Clinical studies

Artificial intelligence is expected to play a groundbreaking role in this year’s discussions, particularly concerning lung cancer imaging and response assessments. As the field of oncology becomes increasingly data-driven, AI technologies are being integrated into clinical workflows, enhancing the precision of diagnoses and treatment protocols. The latest findings showcase AI’s capability to analyze radiological images with higher accuracy than traditional methods, paving the path for quicker and more accurate interventions in lung cancer patients.

Immunotherapy has steadily gained traction in the oncology realm as a preferred approach to treating various cancers, including lung malignancies. ELCC 2025 will feature new research findings that delve into the long-term anti-tumor effectiveness of immunotherapy, especially when combined with chemotherapy. By addressing various non-small cell lung cancer scenarios, the presentations will underscore the potential of combination therapies in achieving better patient outcomes, intensifying the focus on tailored treatment plans based on individual patient profiles.

Furthermore, there has been a growing interest in the comparative efficacy of immunotherapy delivery methods. Recent studies suggest that subcutaneous immunotherapy may offer substantial advantages over traditional intravenous methods, providing both patients and healthcare professionals with a more accessible and less invasive option. This could significantly enhance patient comfort and compliance, offering a streamlined experience in cancer treatment that will surely be a highlight during the sessions at ELCC 2025.

Multiple sessions will also be dedicated to genetic mutations in non-small cell lung cancer, specifically focusing on patients with EGFR mutations. New therapeutic strategies aimed at extending treatments while minimizing adverse effects are critical, especially for patients who experience disease progression after initial therapies. The congress promises to highlight strategies for optimizing combination treatments that spare chemotherapy while effectively managing the disease, ensuring better quality of life for patients undergoing treatment.

Molecular testing is another pivotal area that will be scrutinized at the congress. Experts will evaluate the levels of availability and accessibility of molecular testing globally, aiming to develop strategies to rectify issues related to lung cancer patients receiving treatment without adequate biomarker results. This session is crucial, as biomarker testing is increasingly recognized as essential for personalizing lung cancer treatment plans and improving patient prognoses.

In addition to research discussions, ELCC 2025 will emphasize the critical importance of multidisciplinary decision-making in lung cancer management. The integration of diverse specialties—such as medical oncology, pathology, radiology, and thoracic surgery—ensures comprehensive care and improves overall outcomes for lung cancer patients. By showcasing real-world case studies and clinical experiences, the congress aims to reinforce the value of collaboration and shared decision-making in patient management.

Educational initiatives are paramount at ELCC 2025, with several sessions specifically designed for the continuing education of oncologists and other healthcare providers. The congress aims to equip practitioners with the most up-to-date knowledge and skills essential for managing lung cancer effectively, ensuring they can apply the latest research findings directly to their clinical practice.

Amid advancements in therapeutic strategies, the evolving role of digital health tools and data analytics in oncology cannot be overlooked. These innovative solutions promise to revolutionize patient monitoring and treatment adherence, contributing to the push towards a more integrated healthcare delivery system. At ELCC 2025, experts will explore how digital health innovations can support clinicians in enhancing care efficiency while simultaneously simplifying patient experiences.

The breadth of knowledge shared at ELCC 2025 will be enriched by notable keynote lectures and award presentations. The congress will feature distinguished speakers who will discuss groundbreaking insights and provide updates on cutting-edge research that could reshape how lung cancer is perceived and treated within the medical community. These discussions are vital for inspiring future research trajectories while fostering collaboration across various disciplines in oncology.

At the closing of the event, there will be an emphasis on the collective responsibility of the oncology community to strive for equitable access to care for lung cancer patients worldwide. The injustices faced by underserved populations in accessing screening, treatment, and follow-up care will be central topics, challenging congress attendees to consider the broader implications of their work and research in the fight against lung cancer.

As the European Lung Cancer Congress 2025 approaches, anticipation is mounting regarding the innovative research outcomes that will emerge from this prestigious gathering. The impactful discussions and shared knowledge are expected to significantly influence the treatment paradigms for lung cancer, ultimately leading to improved outcomes for patients grappling with this formidable disease.

The abstracts presented at the congress will be published as a supplement to ESMO Open, ensuring that the insights and research findings are accessible globally. This commitment to disseminating knowledge underscores the importance of continuous learning and collaboration in the oncology community.

The spotlight on cutting-edge research and collaborative strategies during ELCC 2025 will, without a doubt, mark a significant milestone in the ongoing fight against lung cancer, uniting experts and healthcare professionals dedicated to providing the best possible care for patients.

—

Subject of Research: European Lung Cancer Congress 2025
Article Title: European Lung Cancer Congress 2025: A Comprehensive Overview of Innovative Approaches to Thoracic Malignancies
News Publication Date: 20 March 2025
Web References: https://www.esmo.org/meeting-calendar/european-lung-cancer-congress-2025
References: N/A
Image Credits: N/A

Keywords: Lung Cancer, NSCLC, Immunotherapy, Genetic Mutations, Molecular Testing, Digital Health, AI in Oncology, Multidisciplinary Care, Lung Cancer Research, Personalized Medicine, Patient Management, Healthcare Equity.